BioCentury | Apr 15, 2013
Company News

Interneuron, Les Laboratoires Servier, Wyeth-Ayerst sales and marketing update

...to Wyeth-Ayerst by IPIC. Servier withdrew both dexfenfluramine from the market in Europe as well. Wyeth-Ayerst...
...Laboratory at the school. Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Les Laboratoires Servier, Paris, France Wyeth-Ayerst Laboratories...
BioCentury | Apr 15, 2013
Company News

Interneuron metabolic, neurological news

...Redux dexfenfluramine for obesity. Last month, IPIC and partner Wyeth-Ayerst Laboratories (Radnor, Penn.) withdrew Redux and Wyeth-Ayerst's...
BioCentury | Apr 15, 2013
Company News

Interneuron, Wyeth-Ayerst metabolic news

...company on medical and scientific issues relating to the possible heart valve defects associated with Wyeth-Ayerst's...
...Laboratory at Harvard University Medical School. Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Wyeth-Ayerst Laboratories, Philadelphia, Penn. Wyeth-Ayerst...
...company on medical and scientific issues relating to the possible heart valve defects associated with Wyeth-Ayerst's...
BioCentury | Apr 15, 2013
Clinical News

Interneuron, Wyeth-Ayerst regulatory update

...Redux dexfenfluramine, an isomer of fenfluramine marketed by Wyeth-Ayerst. Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Wyeth-Ayerst Laboratories...
BioCentury | Apr 15, 2013
Company News

The Liposome, Wyeth-Ayerst International Inc. deal

...The partners expanded their distribution agreement for LIPO's Abelcet liposomal amphotericin B. Wyeth-Ayerst will market the...
...Wyeth-Ayerst currently markets Abelcet in France and Italy. The Liposome Co. Inc. (LIPO), Princeton, N.J. Wyeth-Ayerst...
BioCentury | Mar 3, 2008
Politics, Policy & Law

Supreme preemption

...case outright. That decision was largely based on a similar case from 2004, Garcia v. Wyeth-Ayerst Laboratories...
BioCentury | Feb 25, 2008
Regulation

Rotavirus showdown

...became Rotarix. Meanwhile, work had been underway for some time at NIH on rhesus-based vaccines. Wyeth-Ayerst Laboratories...
...with the approximately 7,000 children, including 2,000 randomized to receive vaccine, in the dataset that Wyeth-Ayerst...
BioCentury | Aug 14, 2006
Company News

Tranzyme management update

...as VP of business development and licensing, formerly assistant VP of technology licensing of Wyeth's Wyeth-Ayerst Laboratories...
BioCentury | Dec 5, 2005
Company News

Epitan Ltd management update

...business unit at MOG Group Hired: Hank Agersborg as CSO, formerly president of the Wyeth's Wyeth-Ayerst...
BioCentury | Dec 6, 2004
Product Development

Accelerated approval history

...imatinib Ph+ CML 12/20/02 Novartis 1 (1,106) Mylotarg gemtuzumab ozogamicin Acute myeloid leukemia (AML) 5/17/00 Wyeth-Ayerst...
Items per page:
1 - 10 of 407
BioCentury | Apr 15, 2013
Company News

Interneuron, Les Laboratoires Servier, Wyeth-Ayerst sales and marketing update

...to Wyeth-Ayerst by IPIC. Servier withdrew both dexfenfluramine from the market in Europe as well. Wyeth-Ayerst...
...Laboratory at the school. Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Les Laboratoires Servier, Paris, France Wyeth-Ayerst Laboratories...
BioCentury | Apr 15, 2013
Company News

Interneuron metabolic, neurological news

...Redux dexfenfluramine for obesity. Last month, IPIC and partner Wyeth-Ayerst Laboratories (Radnor, Penn.) withdrew Redux and Wyeth-Ayerst's...
BioCentury | Apr 15, 2013
Company News

Interneuron, Wyeth-Ayerst metabolic news

...company on medical and scientific issues relating to the possible heart valve defects associated with Wyeth-Ayerst's...
...Laboratory at Harvard University Medical School. Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Wyeth-Ayerst Laboratories, Philadelphia, Penn. Wyeth-Ayerst...
...company on medical and scientific issues relating to the possible heart valve defects associated with Wyeth-Ayerst's...
BioCentury | Apr 15, 2013
Clinical News

Interneuron, Wyeth-Ayerst regulatory update

...Redux dexfenfluramine, an isomer of fenfluramine marketed by Wyeth-Ayerst. Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Wyeth-Ayerst Laboratories...
BioCentury | Apr 15, 2013
Company News

The Liposome, Wyeth-Ayerst International Inc. deal

...The partners expanded their distribution agreement for LIPO's Abelcet liposomal amphotericin B. Wyeth-Ayerst will market the...
...Wyeth-Ayerst currently markets Abelcet in France and Italy. The Liposome Co. Inc. (LIPO), Princeton, N.J. Wyeth-Ayerst...
BioCentury | Mar 3, 2008
Politics, Policy & Law

Supreme preemption

...case outright. That decision was largely based on a similar case from 2004, Garcia v. Wyeth-Ayerst Laboratories...
BioCentury | Feb 25, 2008
Regulation

Rotavirus showdown

...became Rotarix. Meanwhile, work had been underway for some time at NIH on rhesus-based vaccines. Wyeth-Ayerst Laboratories...
...with the approximately 7,000 children, including 2,000 randomized to receive vaccine, in the dataset that Wyeth-Ayerst...
BioCentury | Aug 14, 2006
Company News

Tranzyme management update

...as VP of business development and licensing, formerly assistant VP of technology licensing of Wyeth's Wyeth-Ayerst Laboratories...
BioCentury | Dec 5, 2005
Company News

Epitan Ltd management update

...business unit at MOG Group Hired: Hank Agersborg as CSO, formerly president of the Wyeth's Wyeth-Ayerst...
BioCentury | Dec 6, 2004
Product Development

Accelerated approval history

...imatinib Ph+ CML 12/20/02 Novartis 1 (1,106) Mylotarg gemtuzumab ozogamicin Acute myeloid leukemia (AML) 5/17/00 Wyeth-Ayerst...
Items per page:
1 - 10 of 407